JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snoek, G. T.
Right arrow Articles by Wirtz, K. W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snoek, G. T.
Right arrow Articles by Wirtz, K. W. A.

J Biol Chem, Vol. 274, Issue 50, 35393-35399, December 10, 1999


Overexpression of Phosphatidylinositol Transfer Protein alpha  in NIH3T3 Cells Activates a Phospholipase A*

Gerry T. SnoekDagger §, Christopher P. Berrie, Teunis B. H. GeijtenbeekDagger , Hester A. van der HelmDagger , Jenny A. CadeéDagger , Cristiano Iurisci, Daniela Corda, and Karel W. A. WirtzDagger

From the Dagger  Centre for Biomembranes and Lipid Enzymology, Department of Lipid Biochemistry, Institute of Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands and  Istituto de Richerche Farmacologiche "Mario Negri," Consorzio Mario Negri Sud, Department of Cell Biology and Oncology, 66030 Santa Maria Imbaro, Chieti, Italy

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In order to investigate the cellular function of the mammalian phosphatidylinositol transfer protein alpha  (PI-TPalpha ), NIH3T3 fibroblast cells were transfected with the cDNA encoding mouse PI-TPalpha . Two stable cell lines, i.e. SPI6 and SPI8, were isolated, which showed a 2- and 3-fold increase, respectively, in the level of PI-TPalpha . Overexpression of PI-TPalpha resulted in a decrease in the duration of the cell cycle from 21 h for the wild type (nontransfected) NIH3T3 (wtNIH3T3) cells and mock-transfected cells to 13-14 h for SPI6 and SPI8 cells. Analysis of exponentially growing cultures by fluorescence-activated cell sorting showed that a shorter G1 phase is mainly responsible for this decrease. The saturation density of the cells increased from 0.20 × 105 cells/cm2 for wtNIH3T3 cells to 0.53 × 105 cells/cm2 for SPI6 and SPI8 cells. However, anchorage-dependent growth was maintained as shown by the inability of the cells to grow in soft agar.

Upon equilibrium labeling of the cells with myo-[3H] inositol, the relative incorporation of radioactivity in the total inositol phosphate fraction was 2-3-fold increased in SPI6 and SPI8 cells when compared with wtNIH3T3 cells. A detailed analysis of the inositol metabolites showed increased levels of glycerophosphoinositol, Ins(1)P, Ins(2)P, and lysophosphatidylinositol (lyso-PtdIns) in SPI8 cells, whereas the levels of phosphatidylinositol (PtdIns) and phosphatidylinositol 4,5-bisphosphate were the same as those in control cells. The addition of PI-TPalpha to a total lysate of myo-[3H]inositol-labeled wtNIH3T3 cells stimulated the formation of lyso-PtdIns. The addition of Ca2+ further increased this formation. Based on these observations, we propose that PI-TPalpha is involved in the production of lyso-PtdIns by activating a phospholipase A acting on PtdIns. The increased level of lyso-PtdIns that is produced in this reaction could be responsible for the increased growth rate and the partial loss of contact inhibition in SPI8 and SPI6 cells. The addition of growth factors (platelet-derived growth factor, bombesin) to these overexpressers did not activate the phospholipase C-dependent degradation of phosphatidylinositol 4,5-bisphosphate.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phospholipid transfer proteins are proteins that are able to transfer phospholipids between membranes in vitro. A major phospholipid transfer protein in mammalian tissues is the phosphatidylinositol transfer protein (PI-TP)1 (1). Recently, two isoforms of PI-TP have been identified (i.e. PI-TPalpha and PI-TPbeta ) that demonstrate differences in cellular localization and in specific lipid transfer activity (2-5).

PI-TPalpha has been purified from both rat and bovine brain (6, 7). Cloning of the cDNA encoding rat brain PI-TPalpha showed that the protein consists of 271 amino acid residues (8). The subsequent isolation of the cDNAs encoding mouse and human PI-TPalpha revealed a high homology between the different mammalian PI-TPs (about 99% amino acid sequence identity) (9, 10). Furthermore, the cross-reactivity of the antibodies raised against bovine PI-TPalpha with a 35-kDa protein from other animals (e.g. rat, mouse, chicken, frog, and lizard) indicates an extensive conservation of the amino acid sequence between species (11). An exception is PI-TP from yeast (i.e. SEC14p) that has the same molecular weight as mammalian PI-TP and comparable phospholipid transfer activities yet shows no homology in the amino acid sequence (12-14).

So far, very little is known about the precise cellular role of mammalian PI-TPalpha . Since PI-TPalpha is able to transfer in vitro PtdIns between membranes in exchange for phosphatidylcholine, it was proposed that PI-TPalpha has a function in the transfer of PtdIns from its site of synthesis in the endoplasmic reticulum to other cellular membranes in order to maintain the level of PtdIns upon metabolism (15-17). PtdIns is a precursor molecule for several intracellular (and possibly also extracellular) lipid messengers, the best characterized of which are 1,2-diacylglycerol and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) (18, 19). These messengers are formed when PtdIns is phosphorylated by PtdIns 4-kinase and phosphatidylinositol 4-phosphate 5-kinase to phosphatidylinositol 4,5-bisphosphate (PtdIns (4,5)P2), which subsequently is degraded by PLC. Other PtdIns derivatives of potential biological significance include those formed in the PtdIns 3-kinase pathway (20, 21), the inositol polyphosphates (22), the cyclic inositolphosphates (23), the glycerophosphoinositols (24-28), and lysophosphatidylinositol (lyso-PtdIns) (29-32). A number of recent studies suggest a role of PI-TPalpha in the production of several of these derivatives. Thomas et al. (33) showed that PI-TPalpha is an essential cytosolic factor to stimulate PLCbeta activity in permeabilized HL60 cells. Furthermore, Cunningham et al. (34) showed that PI-TPalpha promotes the synthesis of PtdIns(4,5)P2. Recently, it was shown in permeabilized human neutrophils that PI-TPalpha stimulates the formylmethionyl leucylphenylanaline-dependent production of phosphatidylinositol 3,4,5-trisphosphate in the presence of PtdIns 3-kinase gamma  (35). Moreover, in permeabilized PC12 cells, PI-TPalpha was found to be one of the three essential factors needed for the ATP-dependent, Ca2+-regulated fusion of secretory granules with the plasma membrane (36). An additional effect on secretion was shown in permeabilized HL60 cells, where PI-TPalpha and PI-TPbeta were able to restore GTPgamma S-stimulated protein secretion in the presence of ADP-ribosylation factor (37). In a cell-free system containing trans-Golgi membranes it was shown that PI-TPalpha (as well as PI-TPbeta ) stimulates the formation of constitutive secretory vesicles and immature secretory granules (38). These results indicate that PI-TP has a function in intracellular membrane traffic from the Golgi to the plasma membrane that may be linked to the production of intracellular lipid messengers.

The above studies, using semi-intact cells and in vitro systems, would indicate that PI-TP acts in different compartments of the cell, in particular at the plasma membrane and at the Golgi membranes. Localization studies by indirect immunofluorescence and by microinjection of fluorescently labeled purified PI-TPalpha and PI-TPbeta into intact mammalian cells have shown that PI-TPalpha is mainly localized in the nucleus and in cluster-like structures in the cytosol and that PI-TPbeta is mainly associated with the Golgi membranes (3, 4, 39, 40). However, upon stimulation of the cells by different growth factors (bombesin, PDGF) that stimulate the phospholipase C-dependent degradation of PtdIns(4,5)P2, accumulation of PI-TPalpha near the plasma membrane was not observed. Thus, no correlation was found between the cellular localization of PI-TPalpha and its proposed sites of action.

In order to gain further insight in the function and the mechanism of action of PI-TPalpha , we have established stable cell lines that overexpress PI-TPalpha . In this paper, we show that overexpression of PI-TPalpha in NIH3T3 cells affects the phenotype, the growth characteristics, and the inositol lipid metabolism of these cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials

The pBluescript vector SK+ was from Stratagene (La Jolla, CA). The anti-PI-TP antibodies were raised in rabbits against synthetic peptides representing the amino acid sequence of predicted epitopes in rat brain PI-TPalpha (39). Geneticin G418 and goat anti-rabbit IgG conjugated with alkaline phosphatase were obtained from Sigma. Goat anti-rabbit IgG conjugated with fluorescein isothiocyanate was from Nordic Immunological Laboratories (Tilburg, The Netherlands). Nitrocellulose membranes were from Schleicher and Schuell. Agar-agar (Agar Noble) was obtained from Difco, RNase A from Roche Molecular Biochemicals, and myo-[2-3H]inositol from Amersham Pharmacia Biotech.

Methods

pSG5-PI-TPalpha Construct The cDNA encoding mouse PI-TPalpha was isolated and cloned into the pBluescript vector (9). The PI-TPalpha cDNA contains a NcoI restriction site around the translational start codon and an EcoRI and XhoI site downstream of the translational stop codon. The NcoI-XhoI fragment was isolated (including the EcoRI site) and ligated into the cloning vector pUC21 (41) in the corresponding restriction sites in order to introduce an extra EcoRI site upstream of the PI-TPalpha cDNA. The resulting EcoRI fragment (containing the complete coding cDNA) was cloned into the unique EcoRI site of the pSG5 expression vector (42). A construct was selected with the cDNA encoding PI-TPalpha in the sense direction. This construct will be denoted as pSG5-PI-TPalpha . The expression of PI-TPalpha will be regulated by the SV40 early promoter, and polyadenylation will be provided by the SV40 poly(A)-adenylation signal (42).

Cell Culture All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% newborn calf serum (NCS) and buffered with NaHCO3 (44 mM) in a 7.5% CO2 humidified atmosphere at 37 °C.

Transfections wtNIH3T3 fibroblast cells were seeded 5 h prior to transfection at a density of 1.3 × 104 cells/cm2. Cells were co-transfected with 30 µg of pSG5-PI-TPalpha and 10 µg of pSV2-neo (43) using a modified calcium phosphate precipitation technique at a CO2 concentration of 7.5% (44). Fresh medium was added 20 h after transfection, and the next day the cells were seeded in new flasks at a density of 2500 cells/10 cm2. After 24 h, neomycin (400 µg/ml Geneticin G418) was added for the selection of neomycin-resistant cells. Fresh medium containing neomycin was added every 4 days, and resistant clones were identified after 2 or 3 weeks of growth.

Gel Electrophoresis and Immunoblotting The PI-TPalpha content of several neomycin-resistant clones was analyzed by immunoblotting with anti-PI-TP antibodies. Confluent cell cultures were washed twice with PBS0 (phosphate-buffered saline without Ca2+ and Mg2+) and removed from the dish by incubation with 8 mM EGTA in PBS0 for 5 min at 37 °C. The cells were centrifuged, and the pellet was stored at -20 °C. A cell homogenate in 0.1 ml of SET buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 0.25 M sucrose) was prepared in a Dounce homogenizer, followed by sonication (1 min at 50 watts). The homogenate was centrifuged for 10 min at 17,000 × g, and the A280 of the supernatant was used to calculate the protein content. 17.5 µg of supernatant protein was loaded on an SDS-polyacrylmide gel, and gel electrophoresis was performed as described (39). The proteins were electrophoretically transferred to a nitrocellulose sheet in a Multiphor II Nova Blot electrophoretic transfer unit (Amersham Pharmacia Biotech) at room temperature applying 1 mA/cm2 of gel for 2 h, and PI-TPalpha was detected as described (39). Quantification of the PI-TPalpha levels on an immunoblot was performed by scanning with a Bio-Rad GS 700 imaging densitometer equipped with an integrating program, with known PI-TPalpha concentrations as a standard.

Growth Assay Cells were seeded at a density of 5 × 104 cells/dish (9 cm2) in DMEM containing 10% NCS. Cell growth was determined by counting the cells every day for 9 days (in duplicate). The saturation density of the different cell lines was determined by seeding 105 cells/dish (9 cm2), and the number of cells was determined after 7 days (in triplicate). The medium was changed every 3 days in both assays.

To determine the ability of the different cell lines to grow in soft agar, 2 × 104 cells were suspended in 0.3% agar in DMEM containing 10% NCS and layered on 0.5% agar in the same medium. Fresh medium was added every 5 days. The colony growth was determined after 3 weeks.

Analysis of the Cell Cycle by Fluorescence-activated Cell Sorting Cells were resuspended in 10 mM EDTA in PBS and washed once with PBS. The cells were fixed in PBS/methanol (3:7, v/v) for 20 min at 4 °C. A 9-fold excess of PBS was added, and the suspension was centrifuged for 5 min at 2500 rpm. The cell pellet was resuspended in 100 µl of PBS containing RNase A (1 mg/ml). Propidium iodide (50 µg/ml) was added, and the cells were incubated for 30 min at 37 °C. The samples were diluted 10-fold with PBS before analysis by fluorescence-activated cell sorting.

Labeling of the Cells: Extraction and Analysis of Inositol Metabolites Two methods were used to analyze the inositol metabolites. The first method was used to obtain a quantitative preparation of the water-soluble total inositol phosphate (IPn) fraction. The second method was used to analyze the composition of the inositol phosphate fraction and of the inositol phospholipids.

Method 1-- The cells were grown in a six-well plate. 60-70% confluent cell cultures were incubated for 48 h with 1 µCi of myo-[3H]inositol in HEPES-buffered DF medium without inositol, containing 2% dialyzed NCS. Cultures were washed twice with PBS0 and scraped in 20 mM Tris buffer, pH 7.4, containing 0.25 M sucrose, 1 mM EDTA, 0.1% Nonidet P-40, and 10 mM LiCl. The cells were sonicated for 1 min in a sonication bath (Branson 1200), and a small sample was removed for protein determination. The cells were extracted by a modified Bligh and Dyer method (45). Upon phase separation, the organic phase was washed twice with MeOH/CHCl3, and the water phases were combined and loaded on a Seppak column (Waters AccellTM Plus QMA Cartridges) Free myo-[3H]inositol was eluted from the column by water, and the total IPn fraction was eluted with 500 mM triethyl ammonium hydrogen carbonate buffer. Radioactivity was determined by liquid scintillation counting. The organic phase, including the protein layer, was acidified by the addition of 0.03 N HCl and washed twice with H2O/MeOH/0.03 N HCl. The inositol phospholipids were separated by thin layer chromatography.

Method 2-- The cells were grown in a 12-well plate and labeled as in method 1 except that 5 µCi of myo-[3H]inositol was used. After labeling, the cells were stimulated for 10 min with PDGF (20 ng/ml) or bombesin (10 nM). Prior to stimulation, 0.5 ml of DF medium without inositol, containing 0.3% bovine serum albumin and 10 mM LiCl, was added to the cells. After 10 min at 37 °C, the incubation was continued for 15 min in the absence or presence of the growth factors. Cultures were washed twice with PBS0 and harvested by scraping in 1 ml of -20 °C MeOH. myo-[3H]Inositol, the inositol phosphate fraction, and the inositol phospholipids were extracted and analyzed as described previously (29, 30).

In Vitro Assay of PI-specific Phospholipase Activity wtNIH3T3 cells were labeled to equilibrium with myo-[3H]inositol (10 µCi) for 48 h in 5 ml of DF medium without inositol containing 2% dialyzed NCS/50-cm2 dish. The cells were scraped in 1.5 ml of 50 mM HEPES, pH 7.4, containing 350 mM sucrose, 154 mM NaCl, 1 mM EDTA, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml phenylmethanesulfonyl fluoride and homogenized by 10 strokes in a Dounce homogenizer. The homogenate was centrifuged at 400 rpm for 2 min in an Eppendorf centrifuge at 4 °C to remove unbroken cells and cell debris, and 0.4 ml of the supernatant, containing about 600,000 dpm in [3H]inositol derivatives, was incubated for 30 min at 37 °C in the absence or presence of Ca2+ (5 mM) and PI-TPalpha . Lipid extraction and analysis were performed as described in method 2 (see above).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mouse NIH3T3 Fibroblast Cells Stably Transfected with the DNA Encoding PI-TPalpha -- The cDNA encoding mouse PI-TPalpha (9) was cloned into the expression vector pSG5, and the vector with PI-TPalpha in the sense orientation is denoted as pSG5-PI-TPalpha .

Mouse NIH3T3 fibroblast cells were co-transfected with both the pSG5-PI-TPalpha and pSV2-neo vectors or with only the pSV2-neo vector (control) by a modified calcium phosphate precipitation technique (44). Stable clones were selected by using the antibiotic Geneticin G418. Several hundred positive neomycin-resistant clones appeared after 2 weeks. From these clones, we selected three stable clones transfected with only the control pSV2-neo vector and 15 clones co-transfected with both the pSG5-PI-TPalpha and the pSV2-neo vector.

The stable clones transfected with the control vector (pSV2-neo) are denoted as OPIx (control vector, clone x), and the clones co-transfected with both pSG5-PI-TPalpha and pSV2-neo are denoted as SPIx (sense PI-TPalpha , clone x). The level of PI-TPalpha expression in these clones was estimated by immunoblotting of the cytosolic fractions of the cells. Two cell lines, SPI6 and SPI8, were selected because they express an increased level of PI-TPalpha as compared with OPI3 and wtNIH3T3 cells. Scanning of the immunostained PI-TPalpha bands indicated that the transfected cell lines SPI6 and SPI8 show a 2- and 3-fold increase in the PI-TPalpha level, respectively, as compared with the wtNIH3T3 and OPI3 cells (Fig. 1A).


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   Analysis of the levels of PI-TPalpha by Western blotting (A) and the morphology of wtNIH3T3 cells, mock-transfected cells, and cells that are transfected with cDNA encoding PI-TPalpha (B). A, 17.5 µg of protein of the 100,000 × g supernatant of the cell lysates was applied in each lane. Cell lysis, electrophoresis, and Western blotting were performed as described under "Experimental Procedures." The density of the PI-TPalpha bands was compared with the density of known concentrations of PI-TPalpha . Gray bars, 10, 20, and 40 ng of purified recombinant mouse PI-TPalpha ; white bars, wtNIH3T3 (1), SPI8 (2), OPI3 (3), and SPI6 (4). B, morphology of wtNIH3T3 (1), SPI6 (2), and SPI8 cells (3).

Morphology, Growth Rate, Density Saturation, and Anchorage-dependent Growth of the Transfected Cell Lines-- Clones that expressed increased amounts of PI-TPalpha displayed an altered morphology (Fig. 1B). These cells (panels 2 and 3) were somewhat smaller and rounder than wtNIH3T3 fibroblasts (panel 1). The stably transfected cell lines displayed an increased growth rate and a higher cell density at confluency (Table I). The doubling time decreased from 21 h for wtNIH3T3 and OPI3 to 13-14 h for SPI6 and SPI8. In addition, the maximal cell density when the cultures are fully confluent increased from 0.20 × 105 cells/cm2 for wtNIH3T3 cells (or OPI3 cells, 0.16 × 105 cells/cm2) to 0.53 × 105 cells/cm2 for SPI6 and SPI8. Despite the difference in expression of PI-TPalpha between SPI6 and SPI8 cells, no significant difference in growth rate or saturation density was observed.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Growth characteristics of the cells that are transfected with the cDNA encoding mouse P1-TPalpha
The cell cycle duration and saturation density were determined by counting the number of cells during growth and upon confluency; the duration of the G1 phase and the percentage of cells in the S phase/mitosis were determined by fluorescence-activated cell sorting analysis of exponentially growing cell cultures. The values are the means of three independent experiments, performed in duplicate.

Analysis of the cellular DNA content in exponentially growing cell cultures by fluorescence-activated cell sorting showed that in wtNIH3T3 cells and in OPI3 cells, respectively, 38 and 35% of the cells were in the S phase/mitosis. For SPI6 cells and SPI8 cells, this percentage was 43 and 46%, respectively (Table I). From these values, and from the duration of the full cell cycle, it was calculated that the G1 phase is significantly shorter in SPI6 cells and SPI8 cells (7-8 h) than the G1 phase in wtNIH3T3 cells or in OPI3 cells (13 h, Table I).

Confluent monolayers of wtNIH3T3 and SPI6/SPI8 cells were different. At full confluency, wtNIH3T3 cultures shed dead cells, while SPI6/SPI8 monolayers started to curl up from the edges of the culture dish, forming a "solid" piece of tissue after some time, indicating a different interaction between the cells.

To investigate whether increased expression of PI-TPalpha led to anchorage-independent growth of the cells, the capacity of the cells to grow in soft agar was investigated. However, none of the cell lines were able to form colonies in soft agar. Therefore, increased expression of PI-TPalpha does not lead to a loss of contact inhibition or to transformation.

Incorporation of myo-[3H]Inositol-- In order to investigate whether overexpression of PI-TPalpha affects the metabolism of the inositol phospholipids, the SPI8/SPI6 cells and wtNIH3T3 cells were labeled with myo-[3H]inositol, and the relative incorporation in the inositol derivatives was determined as described in method 1. After equilibrium labeling of the cells (experimentally established by comparing various periods of labeling) the 3H label in the total IPn fraction was determined (Fig. 2). In wtNIH3T3 cells, 4.4% of the myo-[3H]inositol was incorporated in the IPn fraction. The addition of LiCl had no significant effect on the incorporation. However, incubation with bombesin, in the presence of LiCl, led to a 2-3-fold increase in the incorporation of myo-[3H]inositol in the IPn fraction (Fig. 2). In the SPI6 and SPI8 cells, the percentage of incorporation in the IPn fraction was 2-3-fold higher as compared with wtNIH3T3 cells. Incubation with LiCl or with bombesin (in the presence of LiCl) did not further increase the level of incorporation. This indicates that the stimulation of the PLC-mediated degradation of PtdIns(4,5)P2 is impaired in the cells overexpressing PI-TPalpha .


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Incorporation of myo-[3H]inositol in the total water-soluble inositol phosphate (IPn) fraction in wtNIH3T3, SPI6, and SPI8 cells. Open bars, control cells; gray bars, cells incubated with 10 mM LiCl; black bars, cells incubated with 10 mM LiCl and 10 ng/ml bombesin.

TLC analysis of the inositol phospholipid fraction showed that the relative incorporation of myo-[3H]inositol in PtdIns, PtdIns(4)P or PtdIns(4,5)P2 was similar for wtNIH3T3, SPI6, and SPI8 cells (data not shown).

Analysis of Inositol Metabolites in wtNIH3T3 and SPI8 Cells-- Since the water-soluble IPn fraction consists of a great number of inositol-containing metabolites, it is very possible that the composition of the IPn fraction from the SPI6 and SPI8 cells is different from that of the growth factor-stimulated wtNIH3T3 cells. This possibility was investigated by analysis of the water-soluble inositol metabolites by a high pressure liquid chromatograph connected to an on-line scintillation counter. The labeling and extraction procedures were adapted so as to increase the incorporation of myo-[3H]inositol into the metabolites and to optimize the recovery of lyso-PtdIns, which tends to disappear from the organic phase by frequent wash steps. In agreement with Fig. 2, the initial analyses of metabolites from SPI6 and SPI8 cells gave comparable results. We therefore restricted the detailed analysis to the wtNIH3T3 and SPI8 cells.

As shown in Table II, the total incorporation of myo-[3H]inositol in SPI8 cells was about 70% of that observed in wtNIH3T3 cells, whereas the total amount of protein per well, reflecting the number of cells, was twice as high. Despite this lower total incorporation, the absolute amount of label in the water-soluble inositol phosphates from the SPI8 cells was about twice as high, while the absolute amount of label in the inositol phospholipids was similar to that in the wtNIH3T3 cells.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Absolute and relative incorporation of myo-[3H]inositol in inositol phosphates and inositol phospholipids in wtNIH3T3 and SPI8 cells
The values are the means of three independent experiments, performed in duplicate, ±S.E.

The relative incorporation of myo-[3H]inositol in the inositol phosphate and inositol phospholipid derivatives is shown in Table III. The analysis of the water-soluble inositol phosphates indicates that in SPI8 cells the levels of Ins(1)P and Ins(2)P are significantly (p < 0.05) increased. There was also a 2-fold increase in the level of GroPIns and a small change in the level of Ins(4)P. Low levels of labeled Ins(1,4)P2 and Ins(1,4,5)P3 were also detected, showing no significant difference between wtNIH3T3 and SPI8 cells. Analysis of the inositol phospholipids showed that in SPI8 cells the relative incorporation of myo-[3H]inositol in lyso-PtdIns was clearly increased (p = 0.06). In these cells, the incorporation in PtdIns(4)P was significantly decreased; no changes were observed in the relative labeling of PtdIns and PtdIns(4,5)P2.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Relative incorporation of myo[3H]inositol into inositol derivatives in wtNIH3T3 and SPI8 cells expressed as percentages of the total cellular 3H label
The percentages are the means of three independent experiments, performed in duplicate.

As shown in Fig. 2, the stimulation of the overexpressers with bombesin (10 nM) did not result in an increased incorporation of myo-[3H]inositol in the total IPn fraction, in contrast to what was observed with the wild type cells. In order to investigate whether the PLC-mediated degradation of PtdIns(4,5)P2 is operative in the overexpressers, SPI8 and wild type cells were stimulated with bombesin (10 nM) or with PDGF (20 ng/ml). Analysis of the inositol phosphate fractions showed that stimulation of the wtNIH3T3 cells mainly resulted in an increased incorporation of myo-[3H]inositol in Ins(1,4)P2 and Ins(4)P; there was no significant effect on Ins(1)P and Ins(2)P (Table IV). However, no effect was seen on the level of Ins(4)P or Ins(1,4)P2 in SPI8 cells, indicating the loss of growth factor-stimulated PtdIns(4,5)P2 degradation in these cells.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Relative incorporation of myo-[3H]inositol in Ins(1,4)P2, Ins(1)P, Ins(2)P, and Ins(4)P in wtNIH3T3 and SPI8 cells upon stimulation with bombesin (10 nM) or PDGF (20 ng/ml)
The incorporation is expressed as a percentage of the total 3H label.

The Effect of PI-TPalpha on the Formation of Lyso-PtdIns in Vitro-- The increased level of lyso-PtdIns in the SPI8 cells suggests the activation of a PLA1 and/or PLA2. In order to investigate whether PI-TPalpha was able to stimulate the formation of lyso-PtdIns in vitro, a homogenate of myo-[3H]inositol-labeled wtNIH3T3 cells was incubated with different amounts of this protein in the absence and presence of Ca2+ (5 mM). Each incubation contained about 0.1 µg of endogenous PI-TPalpha . As shown in Fig. 3, incubation with 0.5 µg of PI-TPalpha in the absence of Ca2+ led to a 2-fold increase in the level of lyso-PtdIns. The formation of lyso-PtdIns was further enhanced at a higher PI-TPalpha concentration (2.0 µg). In the presence of Ca2+, the stimulatory effect of PI-TPalpha was more pronounced. The increased levels of lyso-PtdIns were accompanied by a significant decrease in the level of PtdIns (Fig. 3). Under the assay conditions, there was no change in the absolute levels of [3H]PtdIns(4)P and [3H]PtdIns(4,5)P2. The level of lyso-PtdIns in incubations with 0.1 µg of PI-TPalpha (the endogenous level) reflected the level observed in intact cells (compare Fig. 3 and Table III). These results indicate that wtNIH3T3 cells contain a PLA1/PLA2 activity acting on PtdIns that can be activated by PI-TPalpha in a Ca2+-sensitive fashion.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   The formation of lyso-PtdIns in lysates of myo-[3H]inositol-labeled wtNIH3T3 cells incubated with PI-TPalpha in the absence (open symbols) and presence (closed symbols) of 5 mM Ca2+. The 3H-labeled phosphoinositides were separated by TLC, and the distribution of 3H label was determined. The percentages of 3H label in PtdIns (open circle , ) and in lyso-PtdIns (, black-square) are presented. These data are representative for the results of three independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The cellular function of PI-TPalpha has been extensively investigated using permeabilized cells and cell-free systems (33, 36, 38, 46). From these studies it was inferred that PI-TPalpha is involved in the synthesis of PtdIns(4,5)P2, possibly by delivering PtdIns to PtdIns 4-kinase. A more direct approach is to study the PtdIns metabolism in cell lines in which the expression level of PI-TPalpha is changed. In the present study we have established stable mouse NIH3T3 fibroblast cell lines that express a 2-3-fold increase in the levels of PI-TPalpha . These cells were chosen for the transfection experiments because they have a well defined PtdIns metabolism, several well known growth factor receptors, and a significant level of endogenous PI-TPalpha .

As shown in Table I, enhanced levels of PI-TPalpha lead to a dramatic increase in the growth rate of the cells. The cause of the increased growth rate can be manyfold. However, since PI-TPalpha is involved, we have investigated the production of PtdIns metabolites. Two well known PtdIns-derived mitogenic signals are Ins(1,4,5)P3 and 1,2-diacylglycerol, which are formed when a PtdIns(4,5)P2-specific PLC is activated by binding of growth factors to their receptors (18, 19). Another PtdIns derivative with mitogenic activity is lyso-PtdIns that is produced by the PLA2-dependent pathway (24, 25, 29, 30). In the present study, we show that the incorporation of myo-[3H]inositol in the water-soluble inositol phosphate fraction was increased in the SPI8 cells when compared with wtNIH3T3 cells. An increase of 3H-labeled inositol phosphates was also observed in permeabilized PC12 cells upon the addition of purified PI-TPalpha (33, 34, 37). However, in a number of these studies the exact composition of the IPn fraction was not established; an increased "IPn" fraction may include Ins(1)P and Ins(2)P as well as glycerophosphoinositol (products of PLA/lyso-PLA activation) and does not necessarily indicate that levels of Ins(4)P (and hence PLC activity) have increased. Hence, detailed analysis of the inositol phosphate fraction indicated that in SPI8 cells the levels of Ins(1)P and Ins(2)P were significantly increased, whereas the levels of Ins(4)P, Ins(1,4)P2, and Ins(1,4,5)P3 were similar to that in wtNIH3T3 cells. This indicates that overexpression of PI-TPalpha in intact wtNIH3T3 cells has no effect on PtdIns(4,5)P2-specific PLC. Rather, the identified inositol phosphate derivatives are characteristic for the degradation of PtdIns by PLA2 (24, 25, 27). In the latter studies, it was shown that the lyso-PtdIns that is produced upon activation of PLA2 can be degraded by a lysophospholipase to GroPIns. Alternatively, lyso-PtdIns can be degraded by a PLC to Ins(1:2 cyc)P, which, due to the acidic extraction conditions used, may be converted into Ins(1)P and Ins(2)P (23, 47). The activation of a potentially PtdIns-specific PLA in SPI8 cells was confirmed by the analysis of the inositol phospholipid fraction, showing that the level of lyso-PtdIns was 2-3-fold increased as compared with control cells. In line with the enhanced level of lyso-PtdIns, the level of GroPIns was also increased in SPI8 cells. As for the other inositol phospholipids in SPI8 cells, the relative incorporation of myo-[3H]inositol was significantly decreased in PtdIns(4)P, while there were no changes in PtdIns and PtdIns(4,5)P2. Furthermore, the addition of purified PI-TPalpha to a crude lysate of [3H]inositol-labeled wtNIH3T3 cells induced a 2-3-fold increase in the level of lyso-PtdIns most probably derived from PtdIns, since the level of 3H-labeled PtdIns decreased. No significant change was observed in the relative labeling of PtdIns(4)P and PtdIns(4,5)P2. These data strongly suggest that in cells with an increased expression of PI-TPalpha , a potentially PtdIns-specific PLA is constitutively activated. Based on former studies, the activation of a PLA2 is most likely (25, 26). However, activation of a PtdIns-specific PLA1 cannot as yet be excluded. The procedures generally used to extract inositol phospholipids may lead to a loss of the rather water-soluble lyso-PtdIns. This may explain why the PLA-mediated signal transduction pathway has not been detected in the semi-intact cells or in isolated membrane systems upon the addition of PI-TP (33-37). Furthermore, and as indicated above, the detailed analysis of inositol phosphates is required to ascertain whether PLC and/or PLA is activated.

Lyso-PtdIns has been shown to be a signaling molecule itself and could therefore be responsible for the increased growth rate of SPI6 and SPI8 cells. The mechanism by which this molecule acts is not yet fully clear. It has been proposed that lyso-PtdIns can either be released and act by binding to a membrane receptor analogous to the reported membrane receptor for lysophosphatidic acid or act intracellularly by interacting with target proteins (29, 30, 47, 48). Furthermore, lyso-PLA activity on lyso-PtdIns can produce GroPIns, which can itself be phosphorylated to glycerophosphoinositol 4-phosphate, which has been reported to be a novel intracellular messenger of the Ras pathway (28). The increased levels of Ins(1)P and Ins(2)P in extracts of SPI8 cells may represent an increased level of Ins(1:2 cyc)P in intact cells. Increased levels of Ins(1:2 cyc)P have been correlated with a decreased level or activity of the enzyme Ins-1:2-cyc-2 phosphohydrolase (49). An increase in the level of Ins(1:2 cyc)P was thought to be correlated with the loss of contact inhibition (50) and, therefore, could be the reason for the higher cell density observed at confluency of SPI6 and SPI8 cells. Whether the level or activity of Ins(1:2 cyc)P 2-phosphohydrolase actually is changed in SPI6 and SPI8 cells will a the subject of future investigations. Upon activation of PLA2, arachidonic acid may also be released, a precursor of the eicosanoids, which have been shown to participate in cell regulation, such as control of mitogenesis (25, 51).

The growth factors bombesin and PDGF were not able to activate the PLC-mediated degradation of PtdIns(4,5)P2 in SPI6 and SPI8 cells. While in wtNIH3T3 cells, the Ins(4)P production is increased 4-10-fold by bombesin or PDGF, incubation of both SPI6 and SPI8 cells with these growth factors had no effect on either the production of any inositol phosphate or any of the phosphoinositides. The desensitization of the PLC-dependent pathway could be explained by the SPI6 and SPI8 cells expressing either no receptors or impaired receptors for bombesin or PDGF. On the other hand, it has been shown that an increased level of lyso-PtdIns inhibits in vitro a GTPase-activating protein (29). Furthermore, the antibiotic neomycin that is used to select successfully transfected cells could also interfere with the PLC-mediated signal transduction pathway. However, NIH3T3 cells that were transfected with cDNA encoding PLCgamma 1 and selected by neomycin resistance were fully able to respond to PDGF stimulation with increased IPn production (52).2 The activation of PLA2 and the simultaneous desensitization of PLC as observed in the SPI6 and SPI8 cells has also been described for cells transfected with ras or other cytoplasmic (mos, raf) or membrane-associated (src, met, trk) oncogenes but not with nuclear (myc, fos) oncogenes (24). This may suggest that the intracellular mechanisms of action of PI-TPalpha and the above oncogenes have certain steps in common. It is also possible that PI-TPalpha is part of the mechanism used by the oncogene proteins to activate PLA2. On the other hand, activation of PLA2 has also been observed during normal differentiation of neonatal liver cells (53), indicating that increased levels of GroPIns, lyso-PtdIns, and Ins(1)P could also be associated with different stages of differentiation rather than being characteristic of the malignant transformation process.

    ACKNOWLEDGEMENTS

We thank Marcel van der Heyden for assistance with the transfection experiments and Dr. Hans van de Vuurst for help in the fluorescence-activated cell sorting analysis.

    FOOTNOTES

* This work was supported in part by the Netherlands Foundation for Chemical Research, the Netherlands Organization for Scientific Research, the Italian Association for Cancer Research, and the Italian Foundation for Cancer Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 31 30 2534668; Fax: 31 30 2522478; E-mail: g.t.snoek@chem.uu.nl.

2 S. G. Rhee, personal communication.

    ABBREVIATIONS

The abbreviations used are: PI-TP, phosphatidylinositol transfer protein; PtdIns, phosphatidylinositol; GroPIns, glycerophosphoinositol; Ins(4)P, inositol 4-phosphate; PtdIns(4)P, phosphatidylinositol 4- phosphate; PtdIns(4, 5)P2, phosphatidylinositol 4,5-bisphosphate; Ins(1, 4,5)P3, inositol 1,4,5-trisphosphate; Ins(1, 4)P2, inositol 1,4-bisphosphate; PLA, phospholipase A; PLC, phospholipase C; PDGF, platelet-derived growth factor; NCS, newborn calf serum; DMEM, Dulbecco's modified Eagle's medium; DF, DMEM supplemented with Ham's nutrient mixture F-12; wtNIH3T3, wild type (non-transfected) NIH3T3; PBS, phosphate-buffered saline; PBS0, PBS without Ca2+ and Mg2+; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; Ins(1:2 cyc)P, inositol 1:2-cyclic phosphate; IPn, total inositol phosphate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Wirtz, K. W. A. (1997) Biochem. J. 324, 353-360
2. Tanaka, S., and Hosaka, K. (1994) J. Biochem. (Tokyo) 115, 981-984[Abstract/Free Full Text]
3. De Vries, K. J., Heinrichs, A. A. J., Cunningham, E., Brunink, F., Westerman, J., Somerharju, P. J., Cockcroft, S., Wirtz, K. W. A., and Snoek, G. T. (1995) Biochem. J. 310, 643-649
4. De Vries, K. J., Westerman, J., Bastiaens, P. I. H., Jovin, T. M., Wirtz, K. W. A., and Snoek, G. T. (1996) Exp. Cell Res. 227, 33-39[CrossRef][Medline] [Order article via Infotrieve]
5. Westerman, J., de Vries, K. J., Somerharju, P., Timmermans-Hereijgers, J. L. P. M., Snoek, G. T., and Wirtz, K. W. A. (1995) J. Biol. Chem. 270, 14263-14266[Abstract/Free Full Text]
6. Venuti, S. E., and Helmkamp, G. M., Jr. (1988) Biochim. Biophys. Acta 946, 119-128[Medline] [Order article via Infotrieve]
7. van Paridon, P. A., Visser, A. J. W. G., and Wirtz, K. W. A. (1987) Biochim. Biophys. Acta 898, 172-180[Medline] [Order article via Infotrieve]
8. Dickeson, S. K., Lim, C. N., Schuyler, G. T., Dalton, T. P., Helmkamp, G., Jr., and Yarbrough, L. R. (1989) J. Biol. Chem. 264, 16557-16564[Abstract/Free Full Text]
9. Geijtenbeek, T. B. H., de Groot, E., van Baal, J., Brunink, F., Westerman, J., Snoek, G. T., and Wirtz, K. W. A. (1994) Biochim. Biophys. Acta 1213, 309-318[Medline] [Order article via Infotrieve]
10. Dickeson, S. K., Helmkamp, G. M., Jr., and Yarbrough, L. R. (1994) Gene (Amst.) 142, 301-305[CrossRef][Medline] [Order article via Infotrieve]
11. Helmkamp, G. M., Jr. (1990) in Subcellular Biochemistry (Hilderson, H. J., ed), Vol. 16 , pp. 129-174, Plenum Press, New York
12. Bankaitis, V. A., Malehorn, D. E., Emr, S. D., and Greene, R. (1989) J. Cell Biol. 108, 1271-1281[Abstract/Free Full Text]
13. Aitken, J. F., van Heusden, G. P. H., Temkin, M., and Dowhan, W. (1990) J. Biol. Chem. 265, 4711-4717[Abstract/Free Full Text]
14. Bankaitis, V. A., Aitken, J. R., Cleves, A. E., and Dowhan, W. (1990) Nature 347, 561-562[CrossRef][Medline] [Order article via Infotrieve]
15. Wirtz, K. W. A., Helmkamp, G. M., Jr., and Demel, R. A. (1978) in Proteins of the Biological Fluids (Peeters, H., ed) , pp. 25-32, Pergamon Press, Oxford
16. van Paridon, P. A., Gadella, T. W. J, Somerharju, P. J., and Wirtz, K. W. A. (1987) Biochim. Biophys. Acta 903, 68-77[Medline] [Order article via Infotrieve]
17. van Paridon, P. A., Somerharju, P., and Wirtz, K. W. A. (1987) Biochem. Soc. Trans. 15, 321-323[Medline] [Order article via Infotrieve]
18. Berridge, M. J. (1993) Nature 361, 315-325[CrossRef][Medline] [Order article via Infotrieve]
19. Nishizuka, Y. (1995) FASEB J. 9, 484-496[Abstract]
20. Panayotou, G., and Waterfield, M. D. (1993) Bioessays 15, 171-177[CrossRef][Medline] [Order article via Infotrieve]
21. Toker, A., and Cantley, L. C. (1997) Nature 387, 673-676[CrossRef][Medline] [Order article via Infotrieve]
22. Sasakawa, N., Sharif, M., and Hanley, M. R. (1995) Biochem. Pharmacol 150, 137-146
23. Majerus, P. W., Connolly, T. M., Bansal, V. S., Inhorn, R. C., Ross, T. S., and Lips, D. L. (1988) J. Biol. Chem. 263, 3051-3054[Free Full Text]
24. Alonso, T., Morgan, R. O., Marvizon, J. C., Zarbl, H., and Santos, E. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4271-4275[Abstract/Free Full Text]
25. Valitutti, S., Cucchi, P., Colletta, G., Di Filippo, C., and Corda, D. (1991) Cell. Signal. 3, 321-332[CrossRef][Medline] [Order article via Infotrieve]
26. Iacovelli, L., Falasca, M., Valitutti, S., D'Arcangelo, D., and Corda, D. (1993) J. Biol. Chem 268, 20402-20407[Abstract/Free Full Text]
27. Corda, D., and Falasca, M. (1996) Anticancer Res 16, 1341-1350[Medline] [Order article via Infotrieve]
28. Falasca, M., Carvelli, A., Iurisci, C., Qui, R.-G., Symons, M., and Corda, D. (1997) Mol. Biol. Cell 8, 443-453[Abstract]
29. Falasca, M., and Corda, D. (1994) Eur. J. Biochem. 221, 383-389[Medline] [Order article via Infotrieve]
30. Falasca, M., Silletta, M. G., Carvelli, A., Di Francesco, A. L., Fusco, A., Ramakrishna, V., and Corda, D. (1995) Oncogene 10, 2113-2124[Medline] [Order article via Infotrieve]
31. Metz, S. A. (1986) Biochem. Biophys. Res. Commun. 138, 720-727[CrossRef][Medline] [Order article via Infotrieve]
32. Baran, D. T., and Kelly, M. (1987) Endocrinology 122, 930-934[Abstract]
33. Thomas, G. M. H., Cunningham, E., Fensome, A., Ball, A., Totty, N. F., Truong, O., Hsuan, J., and Cockcroft, S. (1993) Cell 74, 919-928[CrossRef][Medline] [Order article via Infotrieve]
34. Cunningham, E., Thomas, G. M. H., Ball, A., Hiles, I., and Cockcroft, S. (1995) Curr. Biol. 5, 775-778[CrossRef][Medline] [Order article via Infotrieve]
35. Kular, G., Loubtchenkov, M, Swigart, P., Whatmore, J., Ball, A., Cockcroft, S., and Wetzker, R. (1997) Biochem. J. 325, 299-301
36. Hay, J. C., and Martin, F. J. (1993) Nature 366, 572-575[CrossRef][Medline] [Order article via Infotrieve]
37. Fensome, A., Cunningham, E., Prosser, S., Tan, S. K., Swigart, P., Thomas, G., Hsuan, J., and Cockcroft, S. (1996) Curr. Biol. 6, 730-738[CrossRef][Medline] [Order article via Infotrieve]
38. Ohashi, M., De Vries, K. J., Frank, R., Snoek, G., Bankaitis, V., Wirtz, K., and Huttner, W. B. (1995) Nature 377, 544-547[CrossRef][Medline] [Order article via Infotrieve]
39. Snoek, G. T., de Wit, I. S. C., van Mourik, J. H. G., and Wirtz, K. W. A. (1992) J. Cell. Biochem. 49, 339-348[CrossRef][Medline] [Order article via Infotrieve]
40. de Vries, K. J., Momchilova-Pankova, A., Snoek, G. T., and Wirtz, K. W. A. (1994) Exp. Cell Res 215, 109-113[CrossRef][Medline] [Order article via Infotrieve]
41. Vieira, J., and Messing, J. (1991) Gene (Amst.) 100, 189-194[CrossRef][Medline] [Order article via Infotrieve]
42. Green, S., Issemann, I., and Sheer, E. (1988) Nucleic Acids Res. 16, 369[Free Full Text]
43. Southern, P. J., and Berg, P. (1982) J. Mol. Appl. Genet. 1, 327-341[Medline] [Order article via Infotrieve]
44. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752[Abstract/Free Full Text]
45. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 96, 634-643
46. Kaufman-Zeh, A., Thomas, G. M. H., Ball, A., Prosser, S., Cunningham, E., Cockcroft, S., and Hsuan, J. J. (1995) Science 268, 1188-1190[Abstract/Free Full Text]
47. Falasca, M., Iurisci, C., Carvelli, A., Sacchetti, A., and Corda, D. (1998) Oncogene 16, 2357-2365[CrossRef][Medline] [Order article via Infotrieve]
48. Van der Bend, R. L., Brunner, J., Jalink, K., van Corven, E. J., Moolenaar, W. H., and van Blitterswijk, W. J. (1992) EMBO J. 11, 2495-2501[Medline] [Order article via Infotrieve]
49. Ross, T. S., and Majerus, P. W. (1992) J. Biol. Chem. 267, 19924-19928[Abstract/Free Full Text]
50. Ross, T. S., Whiteley, B., Graham, R. A., and Majerus, P. W. (1991) J. Biol. Chem. 266, 9086-9092[Abstract/Free Full Text]
51. Piomelli, D. (1995) Curr. Biol. 5, 274-280
52. Kim, H. K., Kim, J. W., Zilberstein, A., Margolis, B., Kim, J. G., Schlessinger, J., and Rhee, S. G. (1991) Cell 65, 435-441[CrossRef][Medline] [Order article via Infotrieve]
53. Falasca, M,., Marino, M., Carvelli, A., Iurisci, C., Leoni, S., and Corda, D. (1996) Eur. J. Biochem 241, 386-392[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
FASEB J.Home page
S. Mariggio, J. Sebastia, B. M. Filippi, C. Iurisci, C. Volonte, S. Amadio, V. De Falco, M. Santoro, and D. Corda
A novel pathway of cell growth regulation mediated by a PLA2{alpha}-derived phosphoinositide metabolite
FASEB J, December 1, 2006; 20(14): 2567 - 2569.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Olayioye, S. Vehring, P. Muller, A. Herrmann, J. Schiller, C. Thiele, G. J. Lindeman, J. E. Visvader, and T. Pomorski
StarD10, a START Domain Protein Overexpressed in Breast Cancer, Functions as a Phospholipid Transfer Protein
J. Biol. Chem., July 22, 2005; 280(29): 27436 - 27442.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. Schenning, C. M. van Tiel, D. van Manen, J. C. Stam, B. M. Gadella, K. W. A. Wirtz, and G. T. Snoek
Phosphatidylinositol transfer protein {alpha} regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor
J. Lipid Res., August 1, 2004; 45(8): 1555 - 1564.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. van Tiel, J. Westerman, M. A. Paasman, M. M. Hoebens, K. W. A. Wirtz, and G. T. Snoek
The Golgi Localization of Phosphatidylinositol Transfer Protein beta Requires the Protein Kinase C-dependent Phosphorylation of Serine 262 and Is Essential for Maintaining Plasma Membrane Sphingomyelin Levels
J. Biol. Chem., June 14, 2002; 277(25): 22447 - 22452.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
J. G. Alb Jr., S. E. Phillips, K. Rostand, X. Cui, J. Pinxteren, L. Cotlin, T. Manning, S. Guo, J. D. York, H. Sontheimer, et al.
Genetic Ablation of Phosphatidylinositol Transfer Protein Function in Murine Embryonic Stem Cells
Mol. Biol. Cell, March 1, 2002; 13(3): 739 - 754.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. van Tiel, J. Westerman, M. Paasman, K. W. A. Wirtz, and G. T. Snoek
The Protein Kinase C-dependent Phosphorylation of Serine 166 Is Controlled by the Phospholipid Species Bound to the Phosphatidylinositol Transfer Protein alpha
J. Biol. Chem., July 7, 2000; 275(28): 21532 - 21538.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available